These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11219155)

  • 1. [Cholesterol-lowering therapy; a recommendation from the Health Council].
    Comans ML
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):244. PubMed ID: 11219155
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholesterol-lowering therapy; a recommendation from the Health Council].
    Simoons ML
    Ned Tijdschr Geneeskd; 2000 Dec; 144(51):2442-4. PubMed ID: 11151651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 4. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 5. Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An opposing view.
    Zweig S
    J Fam Pract; 1988 Jun; 26(6):670-5. PubMed ID: 3132527
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical inquiries. What levels of cholesterol should be treated for primary prevention?
    Seaton TL; Meadows S
    J Fam Pract; 2002 May; 51(5):423. PubMed ID: 12019047
    [No Abstract]   [Full Text] [Related]  

  • 7. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in the secondary prevention of coronary heart disease.
    Veverka A; Jolly JL
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):877-89. PubMed ID: 15500433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1329-30. PubMed ID: 15297284
    [No Abstract]   [Full Text] [Related]  

  • 10. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol-lowering and vascular reactivity in relation to coronary heart disease.
    de Divitiis M; Rubba P
    Nutr Metab Cardiovasc Dis; 1999 Jun; 9(3):133-42. PubMed ID: 10464786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The "healthy" patient with hypercholesterolemia].
    Klose G
    Med Klin (Munich); 2005 Feb; 100(2):99-106; quiz 107-8. PubMed ID: 15711905
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lowering cholesterol in the elderly--yes, no, or maybe?].
    Gogol M
    MMW Fortschr Med; 2006 Mar; 148(12):40-3. PubMed ID: 16626005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 15. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 16. [Broader indication for treatment with statins; the 'heart protection study'].
    Stalenhoef AF; Stuyt PM
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1921-3. PubMed ID: 12404905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering update 2001. Aggressive new goals.
    Fenske TK
    Can Fam Physician; 2001 Feb; 47():303-9. PubMed ID: 11228031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future outlook: changing perspectives on best practice.
    Rader DJ
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S40-4; discussion S45-7. PubMed ID: 11855702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practice guidelines to physicians and their economic aspects; merits and drawbacks].
    Stehouwer CD
    Ned Tijdschr Geneeskd; 1999 Apr; 143(15):776-8. PubMed ID: 10347638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State-of-the-art update and review: clinical trials of lipid-lowering agents.
    Kwiterovich PO
    Am J Cardiol; 1998 Dec; 82(12A):3U-17U; discussion 39U-41U. PubMed ID: 9915657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.